WallStreetZenWallStreetZen

NASDAQ: GILD
Gilead Sciences Inc Stock

$83.73+0.11 (+0.13%)
Updated Jan 27, 2023
GILD Price
$83.73
Fair Value Price
$87.35
Market Cap
$105.02B
52 Week Low
$57.17
52 Week High
$89.74
P/E
31.36x
P/B
4.98x
P/S
2.85x
PEG
0.89x
Dividend Yield
3.49%
Revenue
$27.14B
Earnings
$3.33B
Gross Margin
74.6%
Operating Margin
20.32%
Profit Margin
12.3%
Debt to Equity
1.97
Operating Cash Flow
$10B
Beta
0.57
Next Earnings
Feb 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A

GILD Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Zen Score

Industry Average (44)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GILD scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GILD ($83.73) is undervalued by 4.14% relative to our estimate of its Fair Value price of $87.35 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GILD ($83.73) is not significantly undervalued (4.14%) relative to our estimate of its Fair Value price of $87.35 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GILD ($83.73) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more GILD due diligence checks available for Premium users.

Be the first to know about important GILD news, forecast changes, insider trades & much more!

GILD News

Valuation

GILD fair value

Fair Value of GILD stock based on Discounted Cash Flow (DCF)
Price
$83.73
Fair Value
$87.35
Undervalued by
4.14%
GILD ($83.73) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GILD ($83.73) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GILD ($83.73) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GILD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
31.36x
Industry
30.12x
Market
23.59x
GILD is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GILD is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

GILD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.98x
Industry
5.24x
GILD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GILD price to earnings growth (PEG)

For valuing profitable companies with growth potential
GILD is good value based... subscribe to Premium to read more.
PEG Value Valuation

GILD's financial health

Profit margin

Revenue
$7.0B
Net Income
$1.8B
Profit Margin
25.4%
GILD's Earnings (EBIT) of $5.51B... subscribe to Premium to read more.
Interest Coverage Financials
GILD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$62.6B
Liabilities
$41.5B
Debt to equity
1.97
GILD's short-term assets ($13.55B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GILD's long-term liabilities ($31.08B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GILD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GILD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$2.9B
Investing
-$713.0M
Financing
-$2.1B
GILD's operating cash flow ($9.71B)... subscribe to Premium to read more.
Debt Coverage Financials

GILD vs General Drug Manufacturer Stocks

TickerMarket Cap1d %P/EP/B
GILD$105.02B+0.13%31.36x4.98x
SNY$122.54B-0.66%18.08x1.71x
AMGN$135.34B-0.48%20.26x37.05x
GSK$71.13B-0.11%4.46x6.68x
BMY$154.04B-0.74%23.45x4.71x

Gilead Sciences Stock FAQ

What is Gilead Sciences's quote symbol?

NASDAQ: GILD) Gilead Sciences trades on the NASDAQ under the ticker symbol GILD. Gilead Sciences stock quotes can also be displayed as NASDAQ: GILD.

If you're new to stock investing, here's how to buy Gilead Sciences stock.

What is the 52 week high and low for Gilead Sciences (NASDAQ: GILD)?

(NASDAQ: GILD) Gilead Sciences's 52-week high was $89.74, and its 52-week low was $57.17. It is currently -6.7% from its 52-week high and 46.47% from its 52-week low.

How much is Gilead Sciences stock worth today?

(NASDAQ: GILD) Gilead Sciences currently has 1,254,243,845 outstanding shares. With Gilead Sciences stock trading at $83.73 per share, the total value of Gilead Sciences stock (market capitalization) is $105.02B.

Gilead Sciences stock was originally listed at a price of $1.20 in Dec 31, 1997. If you had invested in Gilead Sciences stock at $1.20, your return over the last 25 years would have been 6,906.69%, for an annualized return of 18.53% (not including any dividends or dividend reinvestments).

How much is Gilead Sciences's stock price per share?

(NASDAQ: GILD) Gilead Sciences stock price per share is $83.73 today (as of Jan 27, 2023).

What is Gilead Sciences's Market Cap?

(NASDAQ: GILD) Gilead Sciences's market cap is $105.02B, as of Jan 28, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Gilead Sciences's market cap is calculated by multiplying GILD's current stock price of $83.73 by GILD's total outstanding shares of 1,254,243,845.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.